Skip to main content

Table 2 Features of classical Hodgkin lymphoma (cHL)-type post-transplant lymphoproliferative disorder (PTLD) subsequent to another PTLD following liver transplantation

From: Classical Hodgkin lymphoma-type and monomorphic-type post-transplant lymphoproliferative disorder following liver transplantation: a case report

Case no. Age/sex Interval Diagnosis EBV positivity Symptoms except lymphoadenopathy Treatment Outcome Reference
1 64 years/M 5 years and 5 months from transplant monomorphic PTLD Fever, abdominal pain Reduction of immunosupression, rituximab, 90Y-IT * Current case
   1 year from the 1st PTLD cHL PTLD Fever Surgery CR  
2 28 years/F 2 years and 2 months from transplant Polymorphic PTLD + Fever Reduction of immunosupression, acyclovir CR 15
   2 years and 5 months from the 1st PTLD cHL PTLD + Fever, splenomegaly Reduction of immunosupression, acyclovir, MOPP, splenectomy CR  
3 9 years/M 8 years from transplant Polymorphic PTLD + Enlarged tonsil, adenoid Reduction of immunosupression, acyclovir CR 12
   6 years and 10 months from the 1st PTLD cHL PTLD + Mediastinal mass COPP, ABV CR  
4 6 years/M 4 years and 2 months from transplant Polymorphic PTLD + None Reduction of immunosupression, gancyclovir CR 14
   1 year and 6 months from the 1st PTLD cHL PTLD + Fever MOPP, ABVD, radiation CR  
  1. PTLD post-transplant lymphoproliferative disorder, cHL classical Hodgkin lymphoma, M male, F female, 90Y-IT yttrium-90-ibritumomab tiuxetan, MOPP mechlorethamine, vincristine, procarbazine, prednisone, COPP cyclophosphamide, vincristin, procarbazine, prednisone, ABV doxorubicin, bleomycin, vinblastine, ABVD doxorubicin, bleomycin, vinblastine, dacarbazine, CR complete remission
  2. *The systemic lymphadenopathy resolved almost completely, except for the splenic hilar lesion composed of cHL-type PTLD